7th March 2025 | 14:00 – 15:00 GMT

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report

or alternatively email medinfo.uk@novartis.com or call 01276 698370

​

 

This meeting is organised and funded by Novartis Pharmaceuticals UK Ltd and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. It is intended for UK healthcare professionals only.

Company products will be discussed at this meeting and United Kingdom prescribing information is available by clicking on the blue button above.

This website is created and funded by Novartis.

​

KISQALI (ribociclib) is indicated for the treatment of women with hormone receptor (HR)−positive, human epidermal growth factor receptor 2 (HER2)−negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.* In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.*^

*KISQALI is not recommended to be used in combination with tamoxifen.^

^KISQALI (ribociclib) Summary of Product Characteristics

​

UK | February 2025 | FA-11353401

​​

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.​